MapLight Therapeutics, Inc. Common Stock
$12.08
-$1.07 (-8.14%)
$12.05Day Range$13.11
Key Statistics
Market Cap
$609.87M
Shares Outstanding
46.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 27, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$13.10
Day High
$13.11
Day Low
$12.05
Volume
402.4K
VWAP
$12.28
Prev Close
$13.15
Transactions
--
Acc. Volume
--
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
PHARMACEUTICAL PREPARATIONSSIC 2834133 employees800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063650-839-4360IPO Oct 27, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001770069
- Composite FIGI
- BBG01JZ5DBQ0
- Share Class FIGI
- BBG01JZ5DBS8
- Ticker Root
- MPLT
- SIC Code
- 2834
About MapLight Therapeutics, Inc. Common Stock (MPLT) Stock
MapLight Therapeutics, Inc. Common Stock (MPLT) closed the 2026-09-15 session at $12.08, down 8.14% versus the previous close (-1.07). The stock opened at $13.10 and traded between $12.05 and $13.11 during that session. Session trading volume was 402K shares. The volume-weighted average price (VWAP) is $12.28.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
MapLight Therapeutics, Inc. Common Stock has a market capitalization of $609.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MPLT is listed on the XNAS exchange. The company employs approximately 133 people. MapLight Therapeutics, Inc. Common Stock is headquartered in REDWOOD CITY, CA. The recorded listing date is 2025-10-27.
On this page you can find market MPLT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.